View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Project
24 June 2019

Phillips-Medisize Pharmaceutical Manufacturing Facility, Wisconsin

Phillips-Medisize is constructing a pharmaceutical manufacturing facility in Hudson, Wisconsin, US.
Phillips-Medisize is developing a new pharmaceutical manufacturing facility in St. Croix Meadows, Hudson, Wisconsin, US. Image courtesy of Phillips-Medisize.
Phillips-Medisize’s facility will manufacture FDA-regulated products. Image courtesy of Marco Verch.
The facility will be utilised for the innovation, development, and manufacturing of pharmaceutical, and medical devices solutions. Image courtesy of Matthew Bates.

Phillips-Medisize is constructing a pharmaceutical manufacturing facility in Hudson, Wisconsin, US.

Free eBook
img

3 Key Tips for a Successful Design Build Project

With supply chain disruptions and inflation creating new challenges for delivery teams, design-build projects are booming. This e-book looks at the 3 essential tips a project delivery team must consider when delivering a successful Design Build project.
by Oracle
Enter your details here to receive your free eBook.

Estimated to cost $40m, the facility will be used for innovation, development and manufacturing of pharmaceutical and medical devices solutions. It will help expand the company’s end-to-end offerings for its customers.

The ground-breaking ceremony for the project took place in February 2019, while the construction is anticipated to be completed by mid-2020.

The facility will employ approximately 250 people when operational.

Location of Philips-Medisize pharmaceutical manufacturing facility

The manufacturing facility is being built on a 34-acre undeveloped site in the St. Croix Meadows redevelopment in Hudson, Wisconsin.

The site was purchased by Phillips-Medisize in October 2018 to expand its high-tech manufacturing operations regulated by the US Food and Drug Administration (FDA) in Wisconsin.

Spanning approximately 132 acres, the St. Croix Meadows site is a mixed-use development site that will include corporate offices, hotels, a retail area, a hi-tech flex space, a conference space, housing and a sports complex.

Details of Phillips-Medisize pharmaceutical manufacturing facility

The pharmaceutical manufacturing facility will occupy a floor area of 230,000ft² in the St. Croix Meadows site.

The facility is FDA-registered and will be outfitted with cleanrooms and state-of-the-art equipment to develop and manufacture FDA-regulated products.

The facility will be in compliance with current good manufacturing practice (cGMP) to follow the quality production standards in the manufacturing process.

“The facility is designed with 60,000ft² of architectural insulated precast and solid precast wall panels.”

The facility is designed with 60,000ft² of architectural insulated precast and solid precast wall panels. The panels feature light colour mix having an etched finish, recessed abrasive blast and bands of form liner to create the desired visual effects.

Contractors involved

Molin Concrete Products was contracted to provide architectural precast wall panels for the Phillips-Medisize pharmaceutical manufacturing facility.

Molin Concrete provided shop drawings and engineering services for the facility during the design development phase and assisted the design team in finalising the drawings for the construction.

The company coordinated with the general contractor Market and Johnson for site access, logistics and safety, as well as for installation plans. Market and Johnson partnered with the US Department of Labour in May 2019 to promote the health and safety of the workers during the construction phase.

River Valley Architects was selected to provide architectural design services, while Ericksen Roed & Associates provides structural engineering services for the facility.

Technology used in Phillips-Medisize’s solutions

Phillips-Medisize provides end-to-end services through an integrated model. It implements the same quality management system (QMS) to ensure the quality of all of its services, a practice that reduces the time consumption at every stage and provides maximum flexibility.

The company has two technology accelerators namely drug delivery device technology accelerators and connected health technology accelerators.

The drug delivery device technology accelerators assist the customers in designing and providing customised drug delivery device according to the desired technology requirement.

The technology accelerators for connected health embed connectivity capabilities to the system. A connected health system contains three main elements, which include a connected device and sensors, digital interface, and a Cloud database platform.

Marketing commentary on Phillips-Medisize

Phillips-Medisize is an indirect subsidiary of Molex. The company provides end-to-end solutions to pharmaceutical, diagnostics and medical devices markets.

The company’s offerings are front-end innovation, design and development, manufacturing development, clinical and commercial manufacturing, as well as post-launch services including Connected Health app and data services.

Headquartered in Wisconsin, US, the company employs more than 5,500 people across 26 manufacturing sites worldwide.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology